SCHEMBL3011323

SCHEMBL3011323

COc1cc(Cc2csc(N3CCC(S(=O)(=O)c4cc(Cl)cc(Cl)c4)CC3)n2)cc(OC)c1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HRH3 Q9Y5N1 2/20 0.35
F2RL3 Q96RI0 12/20 0.35
F2 P00734 1/20 0.35
MAPT P10636 4/20 0.34
HSD17B10 Q99714 2/20 0.34
ALDH1A1 P00352 2/20 0.34
LMNA P02545 2/20 0.34
HPGD P15428 1/20 0.34
USP2 O75604 1/20 0.33
RECQL P46063 1/20 0.33
GPR6 P46095 1/20 0.32
MEN1 O00255 1/20 0.32
GAA P10253 1/20 0.32
MAPK1 P28482 1/20 0.32
KMT2A Q03164 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009031 0.93 PSEN1 (0.36) RAB9ASMN1; SMN2F2RL3F2MAPT
SCHEMBL3020801 0.92 F2 (0.40) RAB9ASMN1; SMN2F2RL3F2MAPT
SCHEMBL3013134 0.91 RAB9A (0.41) RAB9ASMN1; SMN2MAPTHSD17B10ALDH1A1
SCHEMBL3010085 0.91 MAPT (0.43) F2RL3F2MAPTHSD17B10ALDH1A1
SCHEMBL3021485 0.90 MAPT (0.35) RAB9ASMN1; SMN2HRH3MAPTLMNA
SCHEMBL3014057 0.89 MAPT (0.37) RAB9ASMN1; SMN2HRH3F2RL3F2
SCHEMBL3006138 0.89 ALDH1A1 (0.39) SMN1; SMN2HRH3F2RL3F2MAPT
SCHEMBL3016085 0.89 MAPT (0.39) RAB9ASMN1; SMN2F2RL3F2MAPT
SCHEMBL3003810 0.88 GBA1 (0.40) RAB9ASMN1; SMN2F2RL3F2MAPT
SCHEMBL3005424 0.87 DNM1L (0.36) RAB9ASMN1; SMN2HRH3MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885SMN1; SMN2 1/4885HRH3 2846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.